TrialThe oncologist2021

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.

Sara A Hurvitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.